KFC
ABBV icon

Klingenstein Fields & Co’s AbbVie ABBV Stock Holding History

Klingenstein Fields & Co’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.2M Buy
5,537
+462
+9% +$102K 0.05% 102
2025
Q4 		$1.16M Sell
5,075
-110
-2% -$25.1K 0.04% 100
2025
Q3 		$1.2M Sell
5,185
-171
-3% -$34.8K 0.05% 101
2025
Q2 		$994K Sell
5,356
-6,260
-54% -$1.16M 0.04% 100
2025
Q1 		$2.43M Sell
11,616
-39
-0.3% -$7.58K 0.1% 79
2024
Q4 		$2.07M Sell
11,655
-195
-2% -$35.9K 0.08% 80
2024
Q3 		$2.34M Sell
11,850
-164
-1% -$30.6K 0.09% 79
2024
Q2 		$2.06M Sell
12,014
-297
-2% -$49.2K 0.09% 82
2024
Q1 		$2.24M Sell
12,311
-428
-3% -$73.8K 0.09% 83
2023
Q4 		$1.97M Sell
12,739
-2,456
-16% -$358K 0.09% 83
2023
Q3 		$2.26M Buy
15,195
+122
+0.8% +$17.9K 0.11% 80
2023
Q2 		$2.03M Sell
15,073
-85
-0.6% -$12.5K 0.09% 81
2023
Q1 		$2.42M Sell
15,158
-299
-2% -$45.7K 0.12% 78
2022
Q4 		$2.5M Buy
15,457
+452
+3% +$69.3K 0.13% 78
2022
Q3 		$2.01M Buy
15,005
+401
+3% +$57.5K 0.11% 79
2022
Q2 		$2.24M Sell
14,604
-74
-0.5% -$11.3K 0.12% 82
2022
Q1 		$2.38M Hold
14,678
– – 0.1% 82
2021
Q4 		$1.99M Buy
14,678
+285
+2% +$33.7K 0.08% 85
2021
Q3 		$1.55M Sell
14,393
-396
-3% -$45.2K 0.07% 92
2021
Q2 		$1.67M Sell
14,789
-565
-4% -$63.6K 0.07% 88
2021
Q1 		$1.66M Sell
15,354
-17
-0.1% -$1.82K 0.08% 85
2020
Q4 		$1.65M Sell
15,371
-103
-0.7% -$9.9K 0.07% 90
2020
Q3 		$1.35M Buy
15,474
+43
+0.3% +$4.05K 0.07% 100
2020
Q2 		$1.51M Buy
15,431
+194
+1% +$17.1K 0.08% 94
2020
Q1 		$1.16M Sell
15,237
-2,050
-12% -$175K 0.08% 99
2019
Q4 		$1.53M Sell
17,287
-630
-4% -$52.3K 0.08% 94
2019
Q3 		$1.36M Buy
17,917
+422
+2% +$28.9K 0.07% 99
2019
Q2 		$1.27M Sell
17,495
-1
-0% -$79 0.07% 106
2019
Q1 		$1.41M Sell
17,496
-370
-2% -$30.3K 0.08% 106
2018
Q4 		$1.65M Sell
17,866
-115
-0.6% -$10.1K 0.07% 102
2018
Q3 		$1.7M Buy
17,981
+338
+2% +$32.1K 0.06% 105
2018
Q2 		$1.64M Buy
17,643
+183
+1% +$17.9K 0.06% 109
2018
Q1 		$1.65M Sell
17,460
-105
-0.6% -$11.5K 0.06% 111
2017
Q4 		$1.7M Buy
17,565
+375
+2% +$35.3K 0.06% 113
2017
Q3 		$1.53M Sell
17,190
-3,660
-18% -$279K 0.06% 113
2017
Q2 		$1.51M Sell
20,850
-394
-2% -$26.5K 0.06% 112
2017
Q1 		$1.38M Sell
21,244
-2,613
-11% -$164K 0.06% 114
2016
Q4 		$1.49M Sell
23,857
-4,162
-15% -$254K 0.07% 111
2016
Q3 		$1.77M Sell
28,019
-413
-1% -$26.7K 0.08% 100
2016
Q2 		$1.76M Sell
28,432
-328,735
-92% -$20M 0.08% 101
2016
Q1 		$20.4M Sell
357,167
-28,455
-7% -$1.59M 1.02% 35
2015
Q4 		$22.8M Sell
385,622
-7,900
-2% -$455K 1.13% 28
2015
Q3 		$21.4M Sell
393,522
-7,410
-2% -$482K 1.06% 29
2015
Q2 		$26.9M Sell
400,932
-1,015
-0.3% -$66.3K 1.2% 25
2015
Q1 		$23.5M Sell
401,947
-6,596
-2% -$398K 1.04% 32
2014
Q4 		$26.7M Sell
408,543
-8,580
-2% -$541K 1.19% 24
2014
Q3 		$24.1M Sell
417,123
-5,485
-1% -$305K 1.05% 29
2014
Q2 		$23.9M Sell
422,608
-3,099
-0.7% -$163K 1.01% 32
2014
Q1 		$21.9M Sell
425,707
-437,339
-51% -$22.1M 0.98% 33
2013
Q4 		$45.6M Buy
863,046
+268,841
+45% +$13.2M 1.63% 14
2013
Q3 		$26.6M Sell
594,205
-83,938
-12% -$3.72M 1.04% 26
2013
Q2 		$28M Buy
+678,143
New +$29.7M 1% 24

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Klingenstein Fields & Co's ABBV Position: Q1 2026 in Review

Klingenstein Fields & Co increased its AbbVie (ABBV) stake by 9.1% in Q1 2026, buying an estimated $102K and bringing the position to 5,537 shares worth $1.2M. The position accounts for 0.05% of the portfolio, ranked #102.

Klingenstein Fields & Co first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $45.6M in Q4 2013. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Klingenstein Fields & Co held 5,537 shares of AbbVie worth $1.2M as of Q1 2026.
  • Klingenstein Fields & Co bought 462 AbbVie shares in Q1 2026, an estimated $102K.
  • AbbVie made up 0.05% of Klingenstein Fields & Co's portfolio in Q1 2026, its #102 holding.
  • Klingenstein Fields & Co first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
  • Klingenstein Fields & Co's AbbVie position peaked at $45.6M in Q4 2013.
  • 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Klingenstein Fields & Co's 13F filing for Q1 2026, filed 13 May 2026.